Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Italian version of the Edmonton Symptom Assessment System (ESAS)-Total Care (TC): development and psychometric validation in patients undergoing cancer treatment or follow-up.
Ripamonti C, Leporati R, De Feo G, Di Pede P, Toffolatti L, Guglielmo M, La Carpia D, Miccinesi G, Chiesi F. Ripamonti C, et al. Among authors: leporati r. Support Care Cancer. 2022 Mar;30(3):1923-1933. doi: 10.1007/s00520-021-06594-y. Epub 2021 Oct 8. Support Care Cancer. 2022. PMID: 34623487
The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab.
Ligorio F, Fucà G, Zattarin E, Lobefaro R, Zambelli L, Leporati R, Rea C, Mariani G, Bianchi GV, Capri G, de Braud F, Vernieri C. Ligorio F, et al. Among authors: leporati r. Cancers (Basel). 2021 Apr 19;13(8):1964. doi: 10.3390/cancers13081964. Cancers (Basel). 2021. PMID: 33921727 Free PMC article.
Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis.
Gomez-Randulfe I, Silva Díaz S, Escriu C, Mohammed S, Shah R, Benitez Fuentes JD, Cox S, Monaca F, Bria E, García-Campelo MR, Crook B, Talbot T, Leporati R, Balachandran K, Newsom-Davis T, Hughes S, Cove-Smith L, Taylor P, Blackhall F, Califano R. Gomez-Randulfe I, et al. Among authors: leporati r. Ther Adv Med Oncol. 2024 Sep 19;16:17588359241272957. doi: 10.1177/17588359241272957. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39355343 Free PMC article.
Erratum to "Unleashing precision: A review of targeted approaches in pleural mesothelioma" [Crit. Rev. Oncol./Hematol. 203C (2024) 104481].
Occhipinti M, Brambilla M, Di Liello R, Ambrosini P, Lobianco L, Leporati R, Salvarezza M, Vitiello F, Marchesi S, Manglaviti S, Beninato T, Mazzeo L, Proto C, Prelaj A, Ferrara R, Della Corte CM, Lo Russo G, de Braud F, Ganzinelli M, Viscardi G. Occhipinti M, et al. Among authors: leporati r. Crit Rev Oncol Hematol. 2024 Sep 23:104521. doi: 10.1016/j.critrevonc.2024.104521. Online ahead of print. Crit Rev Oncol Hematol. 2024. PMID: 39317528 No abstract available.
Unleashing precision: A review of targeted approaches in pleural mesothelioma.
Occhipinti M, Brambilla M, Di Liello R, Ambrosini P, Lobianco L, Leporati R, Salvarezza M, Vitiello F, Marchesi S, Manglaviti S, Beninato T, Mazzeo L, Proto C, Prelaj A, Ferrara R, Della Corte CM, Lo Russo G, de Braud F, Ganzinelli M, Viscardi G. Occhipinti M, et al. Among authors: leporati r. Crit Rev Oncol Hematol. 2024 Nov;203:104481. doi: 10.1016/j.critrevonc.2024.104481. Epub 2024 Aug 17. Crit Rev Oncol Hematol. 2024. PMID: 39159705 Free article. Review.
Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms.
Angerilli V, Sabella G, Simbolo M, Lagano V, Centonze G, Gentili M, Mangogna A, Coppa J, Munari G, Businello G, Borga C, Schiavi F, Pusceddu S, Leporati R, Oldani S, Fassan M, Milione M. Angerilli V, et al. Among authors: leporati r. Br J Cancer. 2024 Jul;131(1):159-170. doi: 10.1038/s41416-024-02705-8. Epub 2024 May 10. Br J Cancer. 2024. PMID: 38729995 Free PMC article.
22 results